Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VT-122 and Sorafenib in advanced HCC with cachexia risk
NCT01265576Phase 2Unknown
- Sponsor
- Vicus Therapeutics
- Start
- Dec 2010
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of propranolol + etodolac in cancer cachexia, sponsored by Vicus Therapeutics. Status: unknown.
02
Drugs
propranolol + etodolac
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT01265576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01265576.